je.st
news
Tag: results announces
Hasbro (HAS) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS
2014-04-22 02:18:00| Toys - Topix.net
Hasbro released its earnings data on Monday. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.04, American Banking & Market News reports.
Tags: results
estimates
quarterly
earnings
Whirlpool Corporation Announces Annual Stockholders' Meeting Results
2014-04-15 16:32:20| Appliances - Topix.net
Allen, chairman and chief executive officer of Deere & Company, has served as a director since 2010; DiCamillo, partner at Eaglepoint Advisors, LLC, has served as a director since 1997; Dietz, executive vice president and chief marketing officer at Safeway, Inc., has served as a director since 2013; Elliott, executive vice president and chief ... (more)
Tags: results
corporation
meeting
annual
Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C
2014-04-10 13:18:10| Biotech - Topix.net
Gilead Sciences, Inc. today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir for the treatment of chronic hepatitis C virus infection.
Tags: c
results
treatment
phase
Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Nave Patients with Genotype 1 Infection
2014-04-10 07:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Advancement into Phase 3 Trials WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
results
studies
patients
Redhawk Resources Announces Results of Dark Canyon and Prospect...
2014-04-04 20:15:00| Grocery - Topix.net
Redhawk Resources, Inc. is pleased to announce the results of two exploration core drill holes drilled in late 2013 and early 2014 in the Dark Canyon/Prospect Canyon target area.
Tags: results
resources
dark
announces
Sites : [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] next »